<DOC>
	<DOCNO>NCT01568723</DOCNO>
	<brief_summary>The purpose study determine biomarkers predict response ablation therapy patient Barretts esophagus .</brief_summary>
	<brief_title>Betrnet Stem Cells Origins Barrett 's Esophagus Project 3 RF Ablation</brief_title>
	<detailed_description>This Project design identify biologically-based clinically-useful biomarkers tissue risk neoplastic progression well response ablation therapy . These result result improved risk stratification BE well target resource patient candidate ablative therapy , simultaneously provide key information regard origin Barrett 's esophagus .</detailed_description>
	<mesh_term>Barrett Esophagus</mesh_term>
	<criteria>Barrett 's esophagus high grade dysplasia intramucosal ( early ) adenocarcinoma . BE length ≥ 2 cm ≤ 8 cm . Able return every 3 month one year ablation Patients unable compliant followup endoscopy patient tolerate Proton Pump inhibitor preexist esophageal stricture pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Barrett 's esophagus</keyword>
	<keyword>high grade dysplasia</keyword>
	<keyword>ablation</keyword>
	<keyword>radiofrequency ablation</keyword>
	<keyword>esophageal cancer</keyword>
</DOC>